Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates

International Journal of Pharmaceutics
Ruozi BarbaraAndreas M Grabrucker

Abstract

The formation of extracellular aggregates built up by deposits of β-amyloid (Aβ) is a hallmark of Alzheimer's disease (AD). Curcumin has been reported to display anti-amyloidogenic activity, not only by inhibiting the formation of new Aβ aggregates, but also by disaggregating existing ones. However, the uptake of Curcumin into the brain is severely restricted by its low ability to cross the blood-brain barrier (BBB). Therefore, novel strategies for a targeted delivery of Curcumin into the brain are highly desired. Here, we encapsulated Curcumin as active ingredient in PLGA (polylactide-co-glycolic-acid) nanoparticles (NPs), modified with g7 ligand for BBB crossing. We performed in depth analyses of possible toxicity of these NPs, uptake, and, foremost, their ability to influence Aβ pathology in vitro using primary hippocampal cell cultures. Our results show no apparent toxicity of the formulated NPs, but a significant decrease of Aβ aggregates in response to Curcumin loaded NPs. We thus conclude that brain delivery of Curcumin using BBB crossing NPs is a promising future approach in the treatment of AD.

References

Oct 1, 1987·Journal of Clinical and Experimental Neuropsychology·N ButtersJ Wolfe
Jun 4, 2002·Nature Reviews. Molecular Cell Biology·Guy S Salvesen, Colin S Duckett
Apr 23, 2004·Trends in Biochemical Sciences·Yumi Yamamoto, Richard B Gaynor
Dec 14, 2004·The Journal of Biological Chemistry·Fusheng YangGregory M Cole
Jul 16, 2005·Journal of Microencapsulation·R M Mainardes, R C Evangelista
Sep 13, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Luca CostantinoFlavio Forni
Apr 25, 2007·Cellular and Molecular Life Sciences : CMLS·J-M GalloT Rodriguez Martin
Jul 27, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·G TosiF Forni
Nov 15, 2007·Molecular Pharmaceutics·Preetha AnandBharat B Aggarwal
Dec 18, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Raghavendra C MundargiTejraj M Aminabhavi
Feb 6, 2008·Expert Opinion on Drug Delivery·Giovanni TosiMaria Angela Vandelli
Apr 4, 2009·Nanomedicine : Nanotechnology, Biology, and Medicine·Anna Valeria VergoniLuca Costantino
Aug 12, 2009·Neurobiology of Disease·N Joan AbbottDavid J Begley
Nov 4, 2009·Cell and Tissue Research·Andreas GrabruckerTobias M Boeckers
Nov 10, 2009·Nature Biotechnology·Mark Ratner
Jan 1, 2008·Annals of Indian Academy of Neurology·Shrikant Mishra, Kalpana Palanivelu
Jan 27, 2010·The Mount Sinai Journal of Medicine, New York·Daniel P Perl
Feb 6, 2010·Biomaterials·Lucia BondioliMaria A Vandelli
Mar 27, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·G TosiM A Vandelli
Sep 24, 2011·Molecular Neurodegeneration·Andreas M GrabruckerTobias M Boeckers
May 24, 2012·Acta Neuropathologica·Gerard D Schellenberg, Thomas J Montine
Dec 12, 2012·Nanomedicine : Nanotechnology, Biology, and Medicine·Adina N LazarCharles Duyckaerts
Feb 19, 2013·Molecular Aspects of Medicine·László VirágFrancisco Javier Oliver
Jun 24, 2015·Pharmaceutics·Antonietta VilellaGiovanni Tosi
Sep 4, 2015·The AAPS Journal·Murali M YallapuSubhash C Chauhan
May 4, 2016·Tissue Barriers·Andreas M GrabruckerGiovanni Tosi
Nov 4, 2016·Oxidative Medicine and Cellular Longevity·Neil V Klinger, Sandeep Mittal
Mar 14, 2017·Nutrition and Cancer·Parasuraman Aiya SubramaniVenkata Ramireddy Narala

❮ Previous
Next ❯

Citations

Jan 11, 2019·Journal of Functional Biomaterials·Eleonora CalzoniCarla Emiliani
Mar 1, 2019·Pharmaceutics·Daniel Mihai TeleanuRaluca Ioana Teleanu
Oct 16, 2018·Current Molecular Pharmacology·Alexander V ZholosMaksim V Storozhuk
Jan 15, 2018·Journal of Alzheimer's Disease : JAD·P Hemachandra ReddyArubala P Reddy
Dec 14, 2018·Pharmaceutics·Daniel Mihai TeleanuRaluca Ioana Teleanu
Feb 13, 2019·Biomolecules·María L Del Prado-AudeloGerardo Leyva-Gómez
May 8, 2020·International Journal of Molecular Sciences·Matteo BordoniCristina Cereda
Jul 28, 2020·Antioxidants·Helena Tiekou LorinczovaMohammed Gulrez Zariwala
Nov 7, 2019·GeroScience·Oleh LushchakAlexander Vaiserman
Dec 16, 2020·Emerging Topics in Life Sciences·Parasuraman PadmanabhanBalázs Gulyás
May 26, 2020·Mechanisms of Ageing and Development·Alexander VaisermanOleh Lushchak
Nov 28, 2020·International Journal of Nanomedicine·Elif Nur YilmazMehmet Hikmet Ucisik
Feb 9, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Afshin BabazadehSeid Mahdi Jafari
Nov 26, 2019·Current Medicinal Chemistry·Olakunle OladimejiMoganavelli Singh
May 31, 2020·International Journal of Pharmaceutics·Anis AskarizadehAmirhossein Sahebkar
Mar 18, 2021·Journal of Biotechnology·A R NevesS Reis
Apr 18, 2021·Journal of Integrative Medicine·Reem Abdul-LatifThilini Thrimawithana
Jun 17, 2021·Phytotherapy Research : PTR·Khadijeh KhezriAbbas Seyed Zakaryaei
Jun 22, 2021·Current Drug Delivery·Sumel AshiquePooja A Chawla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.